The University of Chicago Header Logo

Connection

Walter M. Stadler to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Walter M. Stadler has written about Antineoplastic Agents.
Walter M. Stadler
Connection Strength
5.899
Antineoplastic Agents
  1. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93.
    View in: PubMed
    Score: 0.233
  2. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013 Aug; 2(4):545-52.
    View in: PubMed
    Score: 0.199
  3. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II? Clin Cancer Res. 2012 May 15; 18(10):2809-16.
    View in: PubMed
    Score: 0.181
  4. Renal cancer therapeutics: now what? Oncology (Williston Park). 2012 Mar; 26(3):301, 304.
    View in: PubMed
    Score: 0.181
  5. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010 Mar 01; 116(5):1272-80.
    View in: PubMed
    Score: 0.157
  6. Other paradigms: randomized discontinuation trial design. Cancer J. 2009 Sep-Oct; 15(5):431-4.
    View in: PubMed
    Score: 0.152
  7. Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. Clin Genitourin Cancer. 2008 Dec; 6 Suppl 1:S22-8.
    View in: PubMed
    Score: 0.144
  8. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.143
  9. The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. Mol Cancer Ther. 2007 Apr; 6(4):1180-5.
    View in: PubMed
    Score: 0.128
  10. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther. 2007 Apr; 6(4):490-3.
    View in: PubMed
    Score: 0.128
  11. Sorafenib. Curr Opin Oncol. 2006 Nov; 18(6):615-21.
    View in: PubMed
    Score: 0.125
  12. Development of growth inhibitory agents in urological and other malignancies. BJU Int. 2006 Sep; 98(3):497-502.
    View in: PubMed
    Score: 0.122
  13. New therapeutic options for renal cell carcinoma. Clin Adv Hematol Oncol. 2006 Jun; 4(6):429-30.
    View in: PubMed
    Score: 0.121
  14. New targets, therapies, and toxicities: lessons to be learned. J Clin Oncol. 2006 Jan 01; 24(1):4-5.
    View in: PubMed
    Score: 0.117
  15. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32.
    View in: PubMed
    Score: 0.113
  16. A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol. 2005 May-Jun; 23(3):150-4.
    View in: PubMed
    Score: 0.113
  17. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Oncol Rep. 2005 Mar; 7(2):116-22.
    View in: PubMed
    Score: 0.111
  18. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22; 391(8):710-721.
    View in: PubMed
    Score: 0.107
  19. Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2024 Jun; 21(3):340-349.
    View in: PubMed
    Score: 0.103
  20. Developing drugs that do not cause tumor regression. Clin Adv Hematol Oncol. 2003 Nov; 1(11):654-5.
    View in: PubMed
    Score: 0.101
  21. Acute bilateral abducens paralysis due to oxaliplatin. J Natl Cancer Inst. 2003 Mar 19; 95(6):488-9.
    View in: PubMed
    Score: 0.097
  22. The role of systemic chemotherapy in the treatment of kidney cancer. Cancer Treat Res. 2003; 116:173-82.
    View in: PubMed
    Score: 0.096
  23. New trial designs to assess antitumor and antiproliferative agents in prostate cancer. Invest New Drugs. 2002 May; 20(2):201-8.
    View in: PubMed
    Score: 0.091
  24. Clinical trial designs for cytostatic agents. J Clin Oncol. 2001 Jun 15; 19(12):3154-5.
    View in: PubMed
    Score: 0.086
  25. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 06 15; 27(12):3317-3328.
    View in: PubMed
    Score: 0.084
  26. Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer. 2021 06 01; 127(11):1827-1835.
    View in: PubMed
    Score: 0.084
  27. Drug dosing in cancer patients with decreased kidney function: A practical approach. Cancer Treat Rev. 2021 Feb; 93:102139.
    View in: PubMed
    Score: 0.083
  28. Development of target-based antineoplastic agents. Invest New Drugs. 2000 Feb; 18(1):7-16.
    View in: PubMed
    Score: 0.078
  29. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol. 2000 Jan; 18(2):371-5.
    View in: PubMed
    Score: 0.078
  30. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 06 15; 393(10189):2404-2415.
    View in: PubMed
    Score: 0.074
  31. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 04; 20(4):581-590.
    View in: PubMed
    Score: 0.073
  32. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol. 1999; 44(1):81-7.
    View in: PubMed
    Score: 0.073
  33. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018 10; 36(5):919-926.
    View in: PubMed
    Score: 0.071
  34. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
    View in: PubMed
    Score: 0.069
  35. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol. 1998 May; 16(5):1820-5.
    View in: PubMed
    Score: 0.069
  36. Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer. 2016 12; 14(6):511-517.
    View in: PubMed
    Score: 0.060
  37. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16.
    View in: PubMed
    Score: 0.060
  38. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18.
    View in: PubMed
    Score: 0.060
  39. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
    View in: PubMed
    Score: 0.056
  40. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52.
    View in: PubMed
    Score: 0.054
  41. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer. 2014 Apr 01; 120(7):976-82.
    View in: PubMed
    Score: 0.051
  42. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014 Mar 01; 120(5):692-701.
    View in: PubMed
    Score: 0.051
  43. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
    View in: PubMed
    Score: 0.051
  44. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013 May; 53(5):491-504.
    View in: PubMed
    Score: 0.049
  45. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80.
    View in: PubMed
    Score: 0.046
  46. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
    View in: PubMed
    Score: 0.044
  47. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011 Oct 20; 29(30):4022-8.
    View in: PubMed
    Score: 0.044
  48. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011 Sep; 78(3):626-30.
    View in: PubMed
    Score: 0.043
  49. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
    View in: PubMed
    Score: 0.043
  50. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):679-86.
    View in: PubMed
    Score: 0.042
  51. Pazopanib in renal cell carcinoma. Clin Cancer Res. 2010 Dec 15; 16(24):5923-7.
    View in: PubMed
    Score: 0.041
  52. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10.
    View in: PubMed
    Score: 0.041
  53. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology. 2010; 78(5-6):340-7.
    View in: PubMed
    Score: 0.041
  54. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol. 2010 Aug; 75(2):152-9.
    View in: PubMed
    Score: 0.040
  55. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6.
    View in: PubMed
    Score: 0.040
  56. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer. 2009 Dec 01; 115(23):5541-9.
    View in: PubMed
    Score: 0.039
  57. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer. 2009 Sep 15; 115(18):4110-7.
    View in: PubMed
    Score: 0.038
  58. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 20; 27(27):4462-8.
    View in: PubMed
    Score: 0.038
  59. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84.
    View in: PubMed
    Score: 0.037
  60. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer. 2008 Jul 01; 113(1):72-7.
    View in: PubMed
    Score: 0.035
  61. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer. 2007 Dec; 5(7):460-3.
    View in: PubMed
    Score: 0.034
  62. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94.
    View in: PubMed
    Score: 0.033
  63. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51.
    View in: PubMed
    Score: 0.032
  64. Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development. Clin Cancer Res. 2007 Mar 15; 13(6):1630-3.
    View in: PubMed
    Score: 0.032
  65. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11; 356(2):125-34.
    View in: PubMed
    Score: 0.032
  66. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007 Jan; 69(1 Suppl):62-79.
    View in: PubMed
    Score: 0.032
  67. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest New Drugs. 2007 Apr; 25(2):181-5.
    View in: PubMed
    Score: 0.031
  68. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006 Nov; 31(6):783-5.
    View in: PubMed
    Score: 0.031
  69. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12.
    View in: PubMed
    Score: 0.030
  70. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Invest New Drugs. 2005 Dec; 23(6):577-81.
    View in: PubMed
    Score: 0.029
  71. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer. 2005 Dec 01; 104(11):2323-33.
    View in: PubMed
    Score: 0.029
  72. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8.
    View in: PubMed
    Score: 0.027
  73. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urol Oncol. 2004 Sep-Oct; 22(5):398-403.
    View in: PubMed
    Score: 0.027
  74. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
    View in: PubMed
    Score: 0.026
  75. Angiogenesis inhibitors in genitourinary cancers. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S41-7.
    View in: PubMed
    Score: 0.025
  76. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7.
    View in: PubMed
    Score: 0.025
  77. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002 Nov 15; 20(22):4478-84.
    View in: PubMed
    Score: 0.024
  78. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75.
    View in: PubMed
    Score: 0.023
  79. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer. 2002 May 15; 94(10):2602-9.
    View in: PubMed
    Score: 0.023
  80. Nilutamide: possible utility as a second-line hormonal agent. Urology. 2001 Dec; 58(6):1016-20.
    View in: PubMed
    Score: 0.022
  81. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20.
    View in: PubMed
    Score: 0.021
  82. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs. 2001; 19(3):255-60.
    View in: PubMed
    Score: 0.021
  83. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000 Sep; 6(9):3400-5.
    View in: PubMed
    Score: 0.020
  84. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer. 2000 Mar 15; 88(6):1317-24.
    View in: PubMed
    Score: 0.020
  85. Kidney cancer. Lancet. 1998 Nov 21; 352(9141):1691-6.
    View in: PubMed
    Score: 0.018
  86. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34.
    View in: PubMed
    Score: 0.017
  87. New chemotherapy regimens for advanced bladder cancer. Semin Urol Oncol. 1998 Feb; 16(1):23-9.
    View in: PubMed
    Score: 0.017
  88. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5461-5471.
    View in: PubMed
    Score: 0.015
  89. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
    View in: PubMed
    Score: 0.012
  90. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. J Cancer Surviv. 2011 Sep; 5(3):255-62.
    View in: PubMed
    Score: 0.011
  91. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
    View in: PubMed
    Score: 0.010
  92. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 Jul 10; 27(20):3312-8.
    View in: PubMed
    Score: 0.009
  93. Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3596s-600s.
    View in: PubMed
    Score: 0.008
  94. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.